These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 2730004)
1. [An analysis of factors influential in improving the survival rate of patients with ovarian cancer]. Ohta M; Tomoda Y; Kano T Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1008-15. PubMed ID: 2730004 [TBL] [Abstract][Full Text] [Related]
2. [Effects of chemotherapy of advanced malignant ovarian tumors]. Ohta M; Sakakibara K; Casanova H; Nishida Y; Kano T; Tomoda Y; Kazato S; Miyazaki T; Arii Y; Umemura S Gan To Kagaku Ryoho; 1985 Nov; 12(11):2208-15. PubMed ID: 4062320 [TBL] [Abstract][Full Text] [Related]
3. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
4. [Studies of second-look operations (SLO) in ovarian cancer]. Yuzawa H Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1310-6. PubMed ID: 2658822 [TBL] [Abstract][Full Text] [Related]
5. [Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer]. Sawada M; Ozaki M; Inagaki M; Hongo J; Hirota Y; Takayama K; Arimoto Y; Wada T; Taki I; Yanagita T Gan To Kagaku Ryoho; 1987 Dec; 14(12):3301-4. PubMed ID: 3120644 [TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: Long-term prognosis after five years. Mizutani K; Takeuchi S; Ohashi Y; Yakushiji M; Nishimura H; Takahashi T; Maruhashi T; Ueda K; Noda K; Watanabe Y; Kawana T; Terashima Y; Ochiai K; Goto S; Takaku F; Motoyoshi K Oncol Rep; 2003; 10(1):127-31. PubMed ID: 12469157 [TBL] [Abstract][Full Text] [Related]
8. [Prognosis and prognostic factor analysis epithelial ovarian cancer]. Wen H; Sun W; Guo Y Zhonghua Fu Chan Ke Za Zhi; 1997 Mar; 32(3):159-62. PubMed ID: 9596891 [TBL] [Abstract][Full Text] [Related]
9. [Cumulative survival rate of chemotherapy with CDDP for malignant ovarian tumors]. Takada M; Usui N; Yoshida K; Hirayama H; Suzuki M; Takeuchi H; Wada H; Iwasa T; Yamamoto T; Nagasawa I Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):333-8. PubMed ID: 2358717 [TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors]. Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198 [TBL] [Abstract][Full Text] [Related]
11. [Treatment and prognostic factors of epithelial ovarian cancer]. Wei L; Qian H; Li W Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):476-9. PubMed ID: 9639741 [TBL] [Abstract][Full Text] [Related]
12. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399 [TBL] [Abstract][Full Text] [Related]
13. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584 [TBL] [Abstract][Full Text] [Related]
14. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer. Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407 [TBL] [Abstract][Full Text] [Related]
15. [Intermittent administration of the combination chemotherapy with cis-platin, adriamycin and cyclophosphamide (cyclic-PAC chemotherapy) for the ovarian cancers]. Inoue M; Nakanishi K; Nakazawa A; Ogawa H; Shimizu H; Saitoh J; Tanaka Y; Ueda G; Tanizawa O Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):347-52. PubMed ID: 2358719 [TBL] [Abstract][Full Text] [Related]
17. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Silva EG; Gershenson DM; Malpica A; Deavers M Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075 [TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576 [TBL] [Abstract][Full Text] [Related]
19. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018 [TBL] [Abstract][Full Text] [Related]
20. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Ryu KS; Kim JH; Ko HS; Kim JW; Ahn WS; Park YG; Kim SJ; Lee JM Gynecol Oncol; 2004 Aug; 94(2):325-32. PubMed ID: 15297169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]